Small engineered scaffold proteins have attracted attention as probes for radionuclide-based molecular imaging. One class of these imaging probes, termed ABD-Derived Affinity ProTeins (ADAPT), have been created using the albumin-binding domain (ABD) of streptococcal protein G as a stable protein scaffold. In this study, we report the development of a clinical lead probe termed ADAPT6 that binds HER2, an oncoprotein overexpressed in many breast cancers that serves as a theranostic biomarker for several approved targeting therapies. Surface-exposed amino acids of ABD were randomized to create a combinatorial library enabling selection of high affinity binders to various proteins. Further, ABD was engineered to rapidly purify ADAPT6, eradicate its binding to albumin and enable rapid blood clearance. Incorporation of a unique cysteine allowed site-specific conjugation to a maleimido derivative of a DOTA chelator, enabling radionuclide labeling, 111 In for SPECT imaging and 68 Ga for PET imaging. Pharmacological studies in mice demonstrated that the fully engineered molecule 111 In/ 68 Ga-DOTA-(HE) 3 -ADAPT6 was specifically bound and taken up by HER2-expressing tumors, with a high tumor-to-normal tissue ratio in xenograft models of human cancer. Unbound tracer underwent rapid renal clearance followed by high renal reabsorption. HER2-expressing xenografts were visualized by gamma-camera or PET by one hour post-infusion. PET experiments demonstrated feasibility for discrimination of xenografts with high or low HER2 expression. Our results offer a preclinical proof of concept for the use of ADAPT probes for non-invasive in vivo imaging.
INTRODUCTION
Specific radionuclide imaging of therapeutic molecular targets in vivo may provide a noninvasive tool for repeatable determination of their expression levels in disseminated cancer in order to stratify patients for a targeted therapy (1) .
Radiolabeled therapeutic monoclonal antibodies have demonstrated utility in visualization of molecular targets (2) (3) (4) . However, poor extravasation and penetration of intact antibodies into tumor masses in combination with slow clearance from blood and tissues (5) cause modest imaging contrast. Besides, antibodies as well as other proteins with molecular weights over 45 kDa accumulate in tumors unspecifically (6) , which may cause false-positive findings. The use of smaller antibody fragments improves tumor-to-organ radioactivity concentration ratios, and therefore imaging contrast (1) . This creates preconditions for better sensitivity.
Mathematical modeling suggests that the smaller the imaging agent is, the better the targeting would be if the affinity is high enough (7) . The smallest immunoglobulin-based imaging agents utilize camelid VHH fragments (15 kDa) and demonstrate very good imaging properties (8) . Still, further size reduction is desirable.
A possible way to generate high-affinity targeting proteins is to combine molecular display techniques (e.g. phage, ribosomal, yeast or bacterial display) with the use of engineered scaffold proteins (9) . Scaffold proteins contain a robust structurally defined framework, which provides rigidity, and a variable surface area, where amino acids are randomized to create libraries for selection of binders. The use of scaffold proteins has enabled the generation of binders with small size (4-20 kDa), well-defined specificity and low nanomolar or subnanomolar affinity. The first scaffold protein for molecular imaging was an affibody molecule targeting HER2, a receptor tyrosine kinase that is overexpressed in cancer and serves as a target for several mAbs and tyrosine kinase inhibitors (10) . In preclinical models, this scaffold protein has demonstrated tumor-to-organ ratios exceeding those of monoclonal antibodies by one-two orders of magnitude (11) . Clinical studies have confirmed the feasibility of imaging of HER2-expressing metastases using affibody molecules within hours after injection (12) . Affibody molecules have also demonstrated successful preclinical imaging of other molecular targets including EGFR (13) , HER3 (14) , and PDGFRβ (16) . Several other targeting scaffold-based proteins, such as anticalins (17) , cysteine-knot peptides (18) , fibronectin domains (19) and designed ankyrin repeats (20) have successfully been used for imaging of therapeutic targets in preclinical studies. Thus, the use of engineered scaffold proteins is a promising approach for development of imaging agents.
Success of imaging depends both on the binding site and the scaffold part of a protein. The binding site determines affinity and specificity of the targeting. The scaffold provides robustness but may also be involved in off-target interactions, such as binding to blood proteins and normal tissues. Extending the scaffold repertoire increases chances for success in selection of an appropriate imaging agent. In this study, we investigated the potential of the albumin-binding domain (ABD) of streptococcal protein G as a scaffold for development of an imaging agent providing a high contrast. ABD is a small (46 amino acids) protein with a three-helical structure, which is independent of disulfide bonds (21) . Important features of ABD include a high melting point, high water solubility and capacity of high fidelity refolding after thermal or chemical denaturation (21) .
Earlier, we have utilized a fusion to ABD to modify biodistribution of therapeutic affibody molecules by binding to albumin in vivo (22) . These studies have demonstrated that ABDcontaining conjugates can be labeled at elevated temperatures without losing specificity to albumin. Further, a second specificity (to TNF-α and HER3) has been engineered into ABD variants to create potential therapeutics with long residence time in circulation (23, 24) .
However, an imaging agent should have a short residence time in blood to avoid a high background during imaging. To fulfill this requirement, binding to albumin should be eradicated.
To test the hypothesis that ABD-derived targeting proteins (designated ADAPTs, ABDDerived Affinity ProTeins) can be used for high-contrast in vivo imaging, a new agent was developed. As a molecular target, the human epidermal growth factor type 2 (HER2) was chosen. HER2 is the molecular target for several therapies in breast cancer (25) and detection of HER2 expression in tumors is required to select anti-HER2 therapy (26) . Thus, an efficient HER2 imaging agent would be useful for the development of personalized therapy of breast cancer. Since HER2 expression in normal adult tissues is very low (27) , the biodistribution of an anti-HER2 ADAPT would depend more on the physical, chemical and biological properties of the scaffold than on its on-target interactions with HER2 expressed in healthy tissues. This provides an advantage in initial studies of novel targeting agents. The selection of ADAPT molecules with affinity towards HER2 is described elsewhere (28) .
MATERIALS AND METHODS
All animal experiments were performed in accordance with national legislation on laboratory animal's protection and have been approved by the ethics committee for Animal Research in Uppsala. Detailed descriptions of materials, equipment and methods used in this study are given in the Supplementary data.
Cell culture
For in vitro studies and for in vivo models with high HER2 expression, Immediately before experiment, HER2 expression in the cell lines was confirmed by measurement of specific binding of radiolabeled anti-HER2 affibody molecule. Cells were cultured in RPMI medium (Flow Irvine), supplemented with 10 % fetal calf serum (Sigma), 2 mM L-glutamine, and PEST (penicillin, 100 IU/mL, and streptomycin, 100 mg/mL; Biokrom Kg).
Tracer design, production and labeling
The binding of the selected molecule, ADAPT , to albumin was deleted by complementing the substitution L37R (28) at the albumin-binding surface with two alanine substitutions (S18Y20). The novel molecule is denoted ADAPT6. A GCSSHEHEHEDEAVDANS-sequence was introduced at the N-terminus both as a tag for immobilized metal ion affinity chromatography (IMAC) purification and as a biodistribution modifier (30) . The variant was designated as C-(HE) 3 -ADAPT6. In addition, an ADAPT6 molecule with an N-terminal GSSHHHHHHDEAVDANS-sequence was also produced for blocking experiments, H 6 -ADAPT. For site-specific labeling, a maleimido-derivative of the versatile DOTA-chelator was conjugated to the unique cysteine introduced at the N-terminus of the (HE) 3 -ADAPT6. The conjugate was designated as DOTA-C-(HE) 3 -ADAPT6. The identity of the conjugate was confirmed by liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS). Purity of the conjugate was determined by reversed phase high-performance liquid chromatography (RP-HPLC). The thermal stability and secondary structure of DOTA-C-(HE) 3 -ADAPT6 and H 6 -ADAPT6 were determined using a JASCO J-810 spectropolarimeter (JASCO, Tokyo, Japan). Binding of DOTA-C-(HE) 3 -ADAPT6 and For labeling with 68 Ga, lyophilized DOTA-C-(HE) 3 -ADAPT6 (50 µg) was reconstituted in 100 µL 1.25 M sodium acetate buffer, pH 3.6.
68
Ga, up to 3 MBq per microgram of DOTA-C-(HE) 3 -ADAPT6, was added to the mixture. The mixture was incubated at 95°C for 30 min.
After labeling, the conjugate was purified using a NAP-5 size-exclusion column equilibrated with PBS. Measurements of labeling yield and radiochemical purity of conjugates were performed by radio-instant thin layer chromatography (ITLC) cross-validated by radio-SDS-PAGE, as described earlier (31) .
To evaluate the stability of the label, the conjugates were incubated at room temperature in a 500-fold molar excess of EDTA for 1 h and then analyzed using radio-ITLC. The experiments were performed in duplicate. In control experiments the conjugates were incubated with PBS only.
In vitro cell binding and processing of radiolabeled ADAPT6
Affinity of binding of radiolabeled 111 In-DOTA-C-(HE) 3 
In vivo evaluation of radiolabeled DOTA-C-(HE) 3 -ADAPT6
Euthanasia was performed under Rompun/Ketalar anesthesia. Animals were purchased from Taconic M&B. A group of four mice was used for each data point. The mice were euthanized at predetermined time points post injection (p.i.) by overdosing of anesthesia followed by heart puncture and exsanguination. Blood and organ samples were collected and their weight and radioactivity were measured. Organ uptake values were calculated as percent of injected activity per gram of tissue (%IA/g).
A study in normal NMRI mice was performed to evaluate the biodistribution pattern of 111 In-DOTA-C-(HE) 3 Targeting of human tumor xenografts with high (SKOV-3) and low (LS174T) expression of HER2 in mice using 68 Ga-DOTA-C-(HE) 3 experiment was to confirm that DOTA-C-(HE) 3 -ADAPT6 labeled with positron-emitting nuclide 68 Ga can specifically target HER2-expressing xenografts, and that the discrimination between tumors with high and low HER2 expression is better at a higher injected protein dose. At the time of experiments, the average animal weight was 19±1 g in both groups. The average weight of SKOV-3 xenografts was 0.21±0.09 g and 0.3±0.2 g for LS174T xenografts.
All animals were injected with 300 kBq 68 Ga-DOTA-C-(HE) 3 -ADAPT6 in 100 µL PBS. For each type of xenograft, the injected protein dose was adjusted with unlabeled DOTA-C-(HE) 3 -ADAPT6 to 1 µg for one group and to 15 µg for the other group.
Imaging
Imaging was performed to obtain a visual confirmation of ex vivo measurements. For gammacamera imaging, two mice bearing SKOV-3 xenografts were injected with 5. 
RESULTS

Tracer design, production and labeling
Analytic RP-HPLC showed a purity of over 95 % for DOTA-C-(HE) 3 -ADAPT6 (Fig. S1 ).
The molecular mass of DOTA-C-(HE) 3 -ADAPT6 was determined by mass spectrometry analysis and showed an excellent agreement with the theoretical value (Fig. S2, expected 7559 Da, found 7560 Da). Circular dichroism measurements (Fig. S3) revealed a high α-helical content and high fidelity refolding after heating to 90 o C, both in agreement with the parental protein scaffold. The melting temperature was 68 o C (Fig. S4) . The binding affinity (K D ) to human recombinant HER2 was 2.5 nM according to SPR analysis (Fig. 1A , Table   S1 ). Deletion of albumin binding was verified by SPR analysis where no reactivity against HSA was detected (Fig. 1B) . Ga. The identity of conjugates was confirmed by radio-SDS-PAGE (Fig. S5) . A challenge with 500-fold excess of EDTA during 2 h did not reveal any release of radioactivity from the conjugates. Specific activities of 1 MBq/µg (7.6 GBq/µmol) and 2.1 MBq/µg (16 GBq/µmol) were obtained for 111 In and 68 Ga-labeled conjugates, respectively.
In vitro cell binding and processing of radiolabeled ADAPT6
According to Interaction Map analysis ( Fig. S6 and S7) , binding of the 111 In-DOTA-C-(HE) 3 
In vivo evaluation of radiolabeled DOTA-C-(HE) 3 -ADAPT6
A first evaluation of 111 In-DOTA-C-(HE) 3 -ADAPT6 was performed in normal NMRI mice (Fig. 2) . The rapid clearance of the tracer from blood (0.36±0.09 %IA/g at 1 h p.i.) confirmed that there was no residual binding to albumin. 111 In-DOTA-C-(HE) 3 -ADAPT6 also cleared rapidly from other organs and tissues (uptake of less than 1 %IA/g at 1 h p.i.) except from kidneys. Low radioactivity in the gastrointestinal tract including content (0.44±0.08 % of injected activity at 1 h p.i.) suggested that hepatobiliary excretion played a minor role in the clearance. The renal uptake was high, 259±30 %IA/g at 1 h p.i.
Biodistribution of 111
In-DOTA-C-(HE) 3 -ADAPT6 in BALB/C nu/nu mice bearing xenografts is shown in Fig. 3 and 4 . The specificity of HER2 targeting in vivo was demonstrated by saturation of HER2 receptors and by the use of HER2-negative Ramos xenografts (Fig. 3) . The use of a saturating amount (300 µg) of non-labeled H resulted in a reduction of tumor uptake of 111 In-DOTA-C-(HE) 3 3.3±0.4 % IA/g (p<0.005). Some reduction of the uptake was observed also in kidneys (p<0.05). Interestingly, the uptake in spleen was significantly (p<0.05) higher in mice injected with 300 µg H 6 -ADAPT6. Uptake in Ramos xenografts (0.112±0.002 % IA/g) was significantly (p<0.05) lower than uptake in SKOV-3 xenografts, on the same level as in muscles.
The biodistribution in normal organs (Fig. 4A ) was characterized by rapid clearance from normal tissues except from kidneys and was in an excellent agreement with the data for NMRI mice. The tumor uptake was 18.7±6.1, 13.9±5.2, and 10.8±2.5 %IA/g at 1, 4 and 24 h p.i., respectively. Although the time points do not differ significantly (p>0.05) there is a clear trend that tumor uptake decreases over time. Such biodistribution pattern provided high tumor-to-organ ratios already at 1 h p.i. (Fig. 4B) . For example, the tumor-to-blood ratio was as high as 43±11 at this time point. At later time points, there was a significant (p<0.05) increase only in tumor-to-blood and tumor-to-lung ratios.
Biodistribution and tumor-to-organ ratios of 68 Ga-DOTA-C-(HE) 3 -ADAPT6 in BALB/C nu/nu mice bearing SKOV-3 (high HER2 expression) and LS174T (low HER2 expression)
xenografts at 1 h p.i. is shown in Tables 1 and 2 . At both injected doses (1 or 15 µg), the uptake in SKOV-3 xenografts was much higher than in LS174T xenografts, which shows that tumor accumulation was dependent on target expression level. In both xenograft models, an increase of injected protein dose caused significant decrease of uptake, suggesting saturable uptake. At higher injected protein dose, the difference between xenografts with high and low HER2 expression was bigger (9.3-fold) than at lower dose (3.6-fold). Although uptake in SKOV-3 xenografts was lower at 15 µg, the tumor-to-organ ratios were not lower. Experimental imaging (Fig. 5) confirmed the biodistribution results. The only normal organ with high uptake of radioactivity was kidney. No other organs were visualized. xenografts with high HER2 expression were clearly visualized with a high contrast using 3 µg 111 In-DOTA-C-(HE) 3 -ADAPT6. Saturation of receptors with DOTA-C-(HE) caused dramatic decrease of tumor uptake (Fig. 5A) . PET imaging (Fig. 5B ) demonstrated that xenografts with high (SKOV-3) and low (LS174T) HER2-expression could be easily distinguished using 15 µg 68 Ga-DOTA-C-(HE) 3 -ADAPT6. 
Imaging
DISCUSSION
Both theoretical calculations and experimental data (5, 7, 34) suggest that size reduction is the most promising way to increase imaging contrast provided by proteinaceous imaging agents. ABD (scaffold size 5.1 kDa without linkers and tags) has a size advantage in comparison with many other scaffold proteins, such as affibody molecules (7 kDa 2. Binding to albumin should be reduced to a level that permits rapid clearance from blood; 3. Off-target interaction of the scaffold should not cause any noticeable uptake in normal tissues.
An optimal affinity (K D ) for imaging agents should be in the range between 10 pM and 10 nM. If K D is lower than 10 pM (very high affinity), pharmacokinetics of the agent would depend heavily on blood flow or vascular permeability. Furthermore, if K D is greater than 10 nM, the off-rate will be too fast, and the retention at specific binding sites might be insufficient (35) . This and previous studies (21, 23, 24) have demonstrated that selection of ADAPT binders with an optimal affinity to several therapeutic targets (HER2, HER3 and TNF-α) is possible. This study has demonstrated that reduction of the affinity to albumin to a non-measurable level is also possible. The data from the first animal study (Fig. 2) demonstrated rapid clearance from blood. Furthermore, these data showed very low uptake in normal tissues (except kidneys), which suggests absence of noticeable off-target interactions.
The high renal uptake is a general feature of all radiometal-labeled scaffold proteins, including nanobodies (36), affibody molecules ( [13] [14] [15] , fibronectin domains (19) and designed ankyrin repeats (20) . This uptake is caused by reabsorption from primary urine in proximal tubuli. After rapid internalization and proteolytic degradation, bulky hydrophilic radiometabolites get trapped inside proximal tubili cells. However, renal metastases are rather rare, and the well-defined shape of kidneys excludes false-positive findings. Moreover, our clinical study with affibody molecules suggests that high renal uptake does not prevent visualization of adrenal metastases and absorbed doses to kidneys permit multiple imaging procedures (12) . Considerations concerning dosimetry aspects of high renal uptake are presented in Supporting Information. In addition, earlier we have shown for affibody molecules that the use of radiohalogen labels yields lipophilic radiometabolites, which "leak" rapidly from kidneys (11, 37) . In the case of slow internalization by cancer cells, the use of radiohalogen labels has very little influence on tumor uptake of affibody molecules (11, 37) .
As internalization of ADAPT6 is also slow (Fig. 1D) , the use of non-residualizing radiohalogen labels may provide ADAPT-based imaging agents with high uptake in tumors but low radioactivity retention in kidneys.
Both in vivo specificity tests (saturation and the use of HER2-negative xenografts) confirmed highly specific targeting of HER2-positive xenografts using 111 In-DOTA-C-(HE) 3 -ADAPT6 (Fig. 3) . Both in vivo specificity tests (saturation and the use of HER2-negative xenografts)
confirmed highly specific targeting of HER2-positive xenografts using 111 In-DOTA-C-(HE) 3 -ADAPT6 (Fig. 3) . Interestingly, the spleen uptake was increased in a saturation experiment. This might be due to weak cross-reactivity with other molecular targets expressed in the spleen or with a target that is taken up by the spleen. Such weak cross-reactivity is primarily Importantly, clearance of 111 In-DOTA-C-(HE) 3 -ADAPT6 was more rapid than clearance of e.g. affibody molecules. As a result, the highest tumor-to-organ ratios were reached very early (Fig. 4B) , which enabled high contrast imaging already at 1 h p.i. (Fig. 5A ). Ability to provide high contrast images shortly after injection offers clear clinical and logistical advantages.
Importantly, it permits the use of short-lived positron emitting radionuclides for labeling and therefore positron-emission tomography (PET) for imaging is feasible (Fig. 5B) .
A rapid blood clearance in combination with high affinity might cause equal uptake of an imaging agent in tumors with high and low target expression. However, this limitation can be circumvented by increasing injected protein dose. We have shown this earlier for affibody molecules in preclinical models (39). In this study, an increase of the injected dose from 1 to 15 µg increased the difference in uptake in xenografts with low and high expression from 3- fold to more than 9-fold. This indicates that during possible clinical translation a dose finding study should be performed to determine an optimal injected dose permitting clear discrimination between tumors with high and low target expression.
In conclusion, ADAPTs can be used as imaging agents that provide high contrast PET imaging of HER2 expression in cancer shortly after injection. This shows that ADAPT is a very promising novel scaffold for development of imaging agents for personalized cancer treatment. Figures captions Fig. 1 . In vitro characterization of DOTA-C-(HE) 3 -ADAPT6. SPR sensorgrams of DOTA-C-(HE) 3 5 . Imaging of HER2 expression in xenografts using radiolabeled DOTA-C-(HE) 3 -ADAPT6. A. Gamma-camera imaging of SKOV-3 xenografts using 111 In-DOTA-C-(HE) 3 -ADAPT6 (3 µg). Contours were derived from a digital photograph and superimposed over images to facilitate interpretation. A control animal (right) was injected with a saturating amount of nonlabeled ADAPT6. B. PET/CT imaging of SKOV-3 (high expression) and LS174T (low expression) xenografts using 68 Ga-DOTA-C-(HE) 3 
